Protagenix Therapeutics is currently trading as an over-the-counter stock. But the company plans to launche on the New York Stock Exchange (NYSE) soon, which will make it easier for everyday investors to buy in.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.11 |
|---|---|
| 52-week range | $0.18 - $4.18 |
| 50-day moving average | $3.76 |
| 200-day moving average | $6.88 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-15.82 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.11 from 2025-05-09
| 1 week (2025-05-06) | -5.18% |
|---|---|
| 1 month (2025-04-11) | 936.67% |
| 3 months (2025-02-13) | 1,031.32% |
| 6 months (2024-11-13) | 378.46% |
| 1 year (2024-05-13) | 131.19% |
|---|---|
| 2 years (2023-05-12) | 42.66% |
| 3 years (2022-05-13) | 18.63% |
| 5 years (2020-05-13) | 5 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -113.49% |
| Return on equity TTM | -236.06% |
| Profit margin | 0% |
| Book value | $1.96 |
| Market Capitalization | $23.6 million |
TTM: trailing 12 months
We're not expecting Protagenic Therapeutics Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Protagenic Therapeutics Inc's shares were split on a 1:14 basis on 4 May 2025 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Protagenic Therapeutics Inc shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Protagenic Therapeutics Inc shares which in turn could have impacted Protagenic Therapeutics Inc's share price.
Over the last 12 months, Protagenic Therapeutics Inc's shares have ranged in value from as little as $0.179 up to $4.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagenic Therapeutics Inc's is 0.29. This would suggest that Protagenic Therapeutics Inc's shares are less volatile than average (for this exchange).
To put Protagenic Therapeutics Inc's beta into context you can compare it against those of similar companies.
Protagenic Therapeutics, Inc. , a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. .
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.